Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MDXH
Upturn stock ratingUpturn stock rating

MDxHealth SA ADR (MDXH)

Upturn stock ratingUpturn stock rating
$2.21
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: MDXH (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $5.55

1 Year Target Price $5.55

Analysts Price Target For last 52 week
$5.55Target price
Low$1.35
Current$2.21
high$3.5

Analysis of Past Performance

Type Stock
Historic Profit -29.22%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 113.84M USD
Price to earnings Ratio -
1Y Target Price 5.55
Price to earnings Ratio -
1Y Target Price 5.55
Volume (30-day avg) 6
Beta -490677.56
52 Weeks Range 1.35 - 3.50
Updated Date 06/29/2025
52 Weeks Range 1.35 - 3.50
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.04

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -41.02%
Operating Margin (TTM) -18.89%

Management Effectiveness

Return on Assets (TTM) -9.57%
Return on Equity (TTM) -1552.23%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 131159921
Price to Sales(TTM) 1.2
Enterprise Value 131159921
Price to Sales(TTM) 1.2
Enterprise Value to Revenue 1.39
Enterprise Value to EBITDA -2.73
Shares Outstanding 49497300
Shares Floating 35018869
Shares Outstanding 49497300
Shares Floating 35018869
Percent Insiders 13.22
Percent Institutions 43.04

Analyst Ratings

Rating 3
Target Price 5.55
Buy 1
Strong Buy 5
Buy 1
Strong Buy 5
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

MDxHealth SA ADR

stock logo

Company Overview

overview logo History and Background

MDxHealth SA ADR (MDXH) is a molecular diagnostics company that provides actionable epigenetic information to personalize cancer treatment. Founded in 2003 in Belgium, it has focused on developing and commercializing tests for prostate cancer diagnosis and management. The company went public via ADR in the United States to expand its reach and investor base.

business area logo Core Business Areas

  • Prostate Cancer Diagnostics: Development and commercialization of SelectMDx and ConfirmMDx tests for prostate cancer diagnosis and management. These tests utilize epigenetic markers to assess a patient's risk of having clinically significant prostate cancer.

leadership logo Leadership and Structure

The leadership team consists of key executives overseeing operations, finance, and research & development. The organizational structure includes departments focused on commercial operations, research, and regulatory affairs.

Top Products and Market Share

overview logo Key Offerings

  • SelectMDx: A urine-based molecular test that helps determine the risk of high-grade prostate cancer. It avoids unnecessary biopsies. Competitors include Exact Sciences' Oncotype DX Genomic Prostate Score and Myriad Genetics' Prolaris.
  • ConfirmMDx: A tissue-based epigenetic test to assess the likelihood of cancer being present when a prior biopsy was negative but suspicion remains. Competitors include Exact Sciences' Oncotype DX Genomic Prostate Score and Myriad Genetics' Prolaris.

Market Dynamics

industry overview logo Industry Overview

The molecular diagnostics industry is rapidly growing, driven by advancements in genomics and epigenetics. The demand for personalized medicine and non-invasive diagnostic tools is increasing. Prostate cancer diagnostics represents a significant market segment.

Positioning

MDxHealth is positioned as a provider of epigenetic-based molecular diagnostic tests for prostate cancer, differentiating itself from competitors that primarily focus on genomic markers. The company has carved a niche by offering tests that provide actionable insights for urologists and patients.

Total Addressable Market (TAM)

The prostate cancer diagnostics market is estimated to be several billion dollars globally. MDxHealth aims to capture a significant portion of this TAM by leveraging its proprietary epigenetic technology and commercial partnerships.

Upturn SWOT Analysis

Strengths

  • Proprietary epigenetic technology
  • Established commercial infrastructure
  • Growing adoption of SelectMDx and ConfirmMDx tests
  • Clear focus on prostate cancer diagnostics

Weaknesses

  • Reliance on a single therapeutic area
  • Competition from larger, more established diagnostic companies
  • Need for continued investment in research and development
  • Reimbursement challenges

Opportunities

  • Expanding applications of epigenetic technology to other cancers
  • Strategic partnerships with pharmaceutical companies
  • Increased awareness and adoption of molecular diagnostics
  • Geographic expansion

Threats

  • Changes in reimbursement policies
  • Emergence of new diagnostic technologies
  • Competition from existing market players
  • Regulatory hurdles

Competitors and Market Share

competitor logo Key Competitors

  • EXAS
  • MYGN

Competitive Landscape

MDxHealth competes with larger, more established diagnostic companies such as Exact Sciences and Myriad Genetics. MDxHealth differentiates itself through its focus on epigenetic markers and its specific tests for prostate cancer diagnosis.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by increased adoption of SelectMDx and ConfirmMDx tests. N/A Data

Future Projections: Future growth is projected to be driven by expanding market share, strategic partnerships, and new product development. N/A Data

Recent Initiatives: Recent initiatives include expanding the commercial team, launching new marketing campaigns, and pursuing strategic partnerships.

Summary

MDxHealth, MDXH, is a specialized molecular diagnostic company focused on prostate cancer. Their epigenetic-based tests offer a unique advantage, contributing to revenue growth. The company faces competition from larger players and needs to manage reimbursement risks. Strategic partnerships and geographic expansion are crucial for future success and profitability. Continued investment in R&D will also be necessary to ensure their continued leadership.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company reports
  • Analyst estimates
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About MDxHealth SA ADR

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-11-04
CEO & Executive Director Mr. Michael K. McGarrity
Sector Healthcare
Industry Diagnostics & Research
Full time employees 312
Full time employees 312

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It also offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.